Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Extends cash runway through at least the first half of 2028Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle...
-
Extends cash runway through at least the first half of 2028Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron...
-
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients
-
Pasithea Tx (Nasdaq: KTTA) activates South Korea trial sites, dosing first NF1 patient in Phase 1/1b NF1 study at Asan Medical Ctr. and Severance Hospital.
-
Pasithea Tx (Nasdaq: KTTA) to present PAS-004 clinical progress at H.C. Wainwright Global Investment Conference on Sept. 10, 2025 in NYC.